EPAS1 and nonpapillary renal cell carcinoma: While many of the treatments commonly used to treat ccRCC act over the downstream effects of VHL loss (VEGFR or PIK3K/mTOR overexpression), there is growing interest in developing specific inhibitors of HIF2A that could act upstream of the activation of hypoxia-modulated genes [17].